AR104847A1 - Formulación de anticuerpo anti-cgrp - Google Patents

Formulación de anticuerpo anti-cgrp

Info

Publication number
AR104847A1
AR104847A1 ARP160101603A ARP160101603A AR104847A1 AR 104847 A1 AR104847 A1 AR 104847A1 AR P160101603 A ARP160101603 A AR P160101603A AR P160101603 A ARP160101603 A AR P160101603A AR 104847 A1 AR104847 A1 AR 104847A1
Authority
AR
Argentina
Prior art keywords
headaches
formulation
cgrp antibody
episodic
chronic
Prior art date
Application number
ARP160101603A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR104847A1 publication Critical patent/AR104847A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Abstract

La presente solicitud se refiere a formulaciones farmacéuticas para anticuerpos anti-CGRP, y métodos para usar los mismos, los cuales son útiles para el tratamiento para migrañas, cefaleas episódicas, cefaleas crónicas, cefaleas en racimos crónicas, y cefaleas en racimos episódicos.
ARP160101603A 2015-06-17 2016-06-01 Formulación de anticuerpo anti-cgrp AR104847A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562180905P 2015-06-17 2015-06-17

Publications (1)

Publication Number Publication Date
AR104847A1 true AR104847A1 (es) 2017-08-16

Family

ID=56131672

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101603A AR104847A1 (es) 2015-06-17 2016-06-01 Formulación de anticuerpo anti-cgrp

Country Status (21)

Country Link
US (3) US11498959B2 (es)
EP (1) EP3310809A1 (es)
JP (1) JP6438599B2 (es)
KR (1) KR102000867B1 (es)
CN (2) CN114948847A (es)
AR (1) AR104847A1 (es)
AU (1) AU2016280555B2 (es)
BR (1) BR112017023374A2 (es)
CA (1) CA2984185A1 (es)
EA (1) EA037580B1 (es)
HK (1) HK1245813A1 (es)
IL (2) IL292562A (es)
JO (1) JO3772B1 (es)
MA (1) MA49726A (es)
MX (1) MX2017016199A (es)
MY (1) MY184266A (es)
NZ (1) NZ737046A (es)
TW (1) TWI725973B (es)
UA (1) UA120881C2 (es)
WO (1) WO2016205037A1 (es)
ZA (1) ZA201707324B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
LT3119431T (lt) 2014-03-21 2024-03-12 Teva Pharmaceuticals International Gmbh Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai
AU2017331592A1 (en) * 2016-09-23 2019-04-11 Teva Pharmaceuticals International Gmbh Treating cluster headache
MX2019003337A (es) 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento para migraña refractaria.
RU2770066C2 (ru) 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
EP3774881A1 (en) * 2018-04-02 2021-02-17 Amgen Inc. Erenumab compositions and uses thereof
WO2019231800A1 (en) * 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
US20220251178A1 (en) * 2019-05-02 2022-08-11 H. Lundbeck A/S Treatment of headache using anti-cgrp antibodieshereof
KR20230157986A (ko) 2021-03-02 2023-11-17 체게에르페 다이어그노스틱스 게엠베하 편투통 발생의 치료 및/또는 저감
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733873A (en) 1992-10-02 1998-03-31 Pharmacia & Upjohn Ab Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
PT1441589E (pt) * 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
EP3417875B1 (en) 2003-02-10 2020-06-17 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
TW200638943A (en) * 2005-01-28 2006-11-16 Wyeth Corp Stabilized liquid polypeptide formulations
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2006096461A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
NZ597082A (en) * 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2626120C (en) 2005-11-14 2012-12-04 Rinat Neuroscience Corp. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
BRPI0721097A2 (pt) 2006-12-11 2014-07-01 Hoffmann La Roche Formulação parenteral de anticorpo abeta
BRPI0806313A2 (pt) * 2007-01-09 2011-09-06 Wyeth Corp Formulação de anticorpo anti-il-13; formulação em aerossol de um anticorpo anti-il-13; formulaçãoliofilizada de um anticorpo anti-il-13; composição farmacêutica para o tratamento de um transtorno relacionado a il-13; fabricação de uma composição farmacêutica ; método de tratamento de um transtorno relacionado a il-13; seringa injetável; dispositivo para administração nasal; emplastro transdérmico; bolsa intravenosa; kit compreendendo pelo menos um recipiente; kit; e seringa injetável previamente enchida
CN101668540A (zh) * 2007-03-22 2010-03-10 英克隆有限责任公司 稳定的抗体制剂
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
CA2684323A1 (en) * 2007-04-18 2008-10-30 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
DK2331090T3 (en) * 2008-09-19 2018-03-12 Pfizer Stable liquid antibody formulation
AU2009333791B2 (en) 2008-10-29 2013-04-04 Ablynx N.V. Formulations of single domain antigen binding molecules
ES2719496T3 (es) * 2008-11-12 2019-07-10 Medimmune Llc Formulación de anticuerpo
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
CA2808975C (en) * 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR20190116563A (ko) * 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
TWI646111B (zh) * 2011-05-20 2019-01-01 艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）組成物及其用途
BR112014009799A2 (pt) 2011-10-24 2017-06-13 Abbvie Inc imunoligantes dirigidos conra tnf
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
CA2898262A1 (en) * 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
LT3119431T (lt) * 2014-03-21 2024-03-12 Teva Pharmaceuticals International Gmbh Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai

Also Published As

Publication number Publication date
US20180134772A1 (en) 2018-05-17
EA201792359A1 (ru) 2018-05-31
JP2018517727A (ja) 2018-07-05
AU2016280555B2 (en) 2018-11-15
UA120881C2 (uk) 2020-02-25
JP6438599B2 (ja) 2018-12-19
US11498959B2 (en) 2022-11-15
WO2016205037A1 (en) 2016-12-22
NZ737046A (en) 2019-09-27
EA037580B1 (ru) 2021-04-16
US20230159628A1 (en) 2023-05-25
EP3310809A1 (en) 2018-04-25
ZA201707324B (en) 2020-01-29
MY184266A (en) 2021-03-30
KR20180002858A (ko) 2018-01-08
TWI725973B (zh) 2021-05-01
JO3772B1 (ar) 2021-01-31
CN114948847A (zh) 2022-08-30
CA2984185A1 (en) 2016-12-22
CN107787229A (zh) 2018-03-09
IL292562A (en) 2022-06-01
HK1245813A1 (zh) 2018-08-31
TW201711697A (zh) 2017-04-01
US20220112277A1 (en) 2022-04-14
KR102000867B1 (ko) 2019-07-16
IL255443B (en) 2022-06-01
MX2017016199A (es) 2018-03-01
IL255443A0 (en) 2017-12-31
BR112017023374A2 (pt) 2018-07-24
AU2016280555A1 (en) 2017-11-16
MA49726A (fr) 2020-06-10

Similar Documents

Publication Publication Date Title
AR104847A1 (es) Formulación de anticuerpo anti-cgrp
CL2018001000A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr.
ECSP18008905A (es) Tricíclicos sustituidos y método para usarlos.
BR112019012342A2 (pt) anticorpos il-11
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
EA201691991A1 (ru) Мультиспецифические антитела
MD3827845T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
BR112019012343A2 (pt) anticorpos il-11ra
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
CO2017003005A2 (es) Anticuerpos anti-mfi2
BR112018010102A2 (pt) conjugados farmacêuticos de anticorpos sítio-específicos para her2
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
CO2017005566A2 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
BR112016019389A8 (pt) Vacina, e, peptídeo